Proinflammatory and Vasoactive Effects of Aβ in the Cerebrovasculature
暂无分享,去创建一个
N. Patel | D. Paris | K. Townsend | D. Obregon | M. Mullan | K P Townsend | D Obregon | A Quadros | N Patel | Ch Volmar | D Paris | M Mullan | A. Quadros | C. Volmar | Michael J. Mullan | Kirk P. Townsend | Demian Obregon
[1] C. Iadecola,et al. Cerebrovascular autoregulation is profoundly impaired in mice overexpressing amyloid precursor protein. , 2002, American journal of physiology. Heart and circulatory physiology.
[2] R. Kalaria,et al. Increased collagen content of cerebral microvessels in Alzheimer's disease , 1995, Brain Research.
[3] D. Premkumar,et al. Molecular aspects of inflammatory and immune responses in Alzheimer's disease , 1996, Neurobiology of Aging.
[4] F. Crawford,et al. Role of Peroxynitrite in the Vasoactive and Cytotoxic Effects of Alzheimer's β-Amyloid1–40Peptide , 1998, Experimental Neurology.
[5] A. Guerguerian,et al. Key role for cyclooxygenase-2 in PGE2 and PGF2α receptor regulation and cerebral blood f low of the newborn. , 1997, American journal of physiology. Regulatory, integrative and comparative physiology.
[6] T. Montine,et al. Elevated CSF prostaglandin E2 levels in patients with probable AD. , 1999, Neurology.
[7] M. Mullan,et al. β-Amyloid-mediated vasoactivity and vascular endothelial damage , 1996, Nature.
[8] R. Roos,et al. Dementia in hereditary cerebral hemorrhage with amyloidosis‐Dutch type is associated with cerebral amyloid angiopathy but is independent of plaques and neurofibrillary tangles , 2001, Annals of neurology.
[9] George A. Carlson,et al. Exogenous Aβ1–40 Reproduces Cerebrovascular Alterations Resulting from Amyloid Precursor Protein Overexpression in Mice , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[10] J. C. Torre. Impaired Cerebromicrovascular Perfusion: Summary of Evidence in Support of Its Causality in Alzheimer's Disease , 2000 .
[11] H. Wiśniewski,et al. Migration of perivascular cells into the neuropil and their involvement in β-amyloid plaque formation , 2004, Acta Neuropathologica.
[12] P. R. Hof,et al. Pathological alterations of the cerebral microvasculature in Alzheimer's disease and related dementing disorders , 1994, Acta Neuropathologica.
[13] Fiona Crawford,et al. Soluble Alzheimers β-amyloid constricts the cerebral vasculature in vivo , 1998, Neuroscience Letters.
[14] O. Bugiani,et al. Thickening of the basement membrane of cortical capillaries in Alzheimer's disease , 2004, Acta Neuropathologica.
[15] C. Soto,et al. Alzheimer's β‐amyloid vasoactivity: identification of a novel β‐amyloid conformational intermediate , 1998 .
[16] D. Cornfield,et al. Aβ-peptides enhance vasoconstriction in cerebral circulation , 2001 .
[17] L. Thal,et al. Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease , 1996, Neurology.
[18] C. Iadecola,et al. Increased Susceptibility to Ischemic Brain Damage in Transgenic Mice Overexpressing the Amyloid Precursor Protein , 1997, The Journal of Neuroscience.
[19] A. Fendrick. Developing an economic rationale for the use of selective COX-2 inhibitors for patients at risk for NSAID gastropathy. , 2002, Cleveland Clinic journal of medicine.
[20] C. Lemere,et al. Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. , 2001, The American journal of pathology.
[21] D. Borchelt,et al. SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein , 1999, Nature Neuroscience.
[22] M. Shigeta,et al. A Follow-Up Study of the Family with the Swedish APP 670/671 Alzheimer’s Disease Mutation , 1999, Dementia and Geriatric Cognitive Disorders.
[23] J. Price,et al. Beta-amyloid-induced coronary artery vasoactivity and endothelial damage. , 1997, Journal of cardiovascular pharmacology.
[24] C. Iadecola,et al. Abeta 1-40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[25] D. Selkoe,et al. Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease , 1989, Journal of Neuroimmunology.
[26] L. Lue,et al. Inflammation, A beta deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration. , 1996, Journal of neuropathology and experimental neurology.
[27] R. Mrak,et al. Interleukin‐1 Expression in Different Plaque Types in Alzheimer's Disease: Significance in Plaque Evalution , 1995, Journal of neuropathology and experimental neurology.
[28] V. Fischer,et al. Altered angioarchitecture in selected areas of brains with Alzheimer's disease , 2004, Acta Neuropathologica.
[29] P. Amenta,et al. The basement membrane in pathology. , 1983, Laboratory investigation; a journal of technical methods and pathology.
[30] Mark A. Smith,et al. Cerebrovascular muscle atrophy is a feature of Alzheimer's disease , 1998, Brain Research.
[31] E. Ellis,et al. Isoprostanes: free radical-generated prostaglandins with constrictor effects on cerebral arterioles. , 1997, Stroke.
[32] A. Placzek,et al. Aβ Vasoactivity in Vivo , 2000 .
[33] D. Borchelt,et al. Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer’s Disease neuropathology , 2002, Neurobiology of Aging.
[34] P. Hof,et al. Brain Microvascular Changes in Alzheimer's Disease and Other Dementias a , 1997, Annals of the New York Academy of Sciences.
[35] J. C. Torre,et al. Alzheimer Disease as a Vascular Disorder: Nosological Evidence , 2002 .
[36] K. Ashe,et al. Ibuprofen Suppresses Plaque Pathology and Inflammation in a Mouse Model for Alzheimer's Disease , 2000, The Journal of Neuroscience.
[37] J. Wegiel,et al. Ultrastructural studies of the cells forming amyloid in the cortical vessel wall in Alzheimer's disease , 2004, Acta Neuropathologica.
[38] W F Stewart,et al. Risk of Alzheimer's disease and duration of NSAID use , 1997, Neurology.
[39] W. Grizzle,et al. Dissociation of Cyclic Inositol Phosphohydrolase Activity from Annexin III (*) , 1996, The Journal of Biological Chemistry.
[40] M. Mullan,et al. Characteristics of thein VitroVasoactivity of β-Amyloid Peptides , 1998, Experimental Neurology.
[41] Tetsuo Hashimura,et al. Morphological Changes of Blood Vessels in the Brain with Alzheimer's Disease , 1988 .
[42] George A. Carlson,et al. Alterations in Cerebral Blood Flow and Glucose Utilization in Mice Overexpressing the Amyloid Precursor Protein , 2002, Neurobiology of Disease.
[43] R. Veerhuis,et al. Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain , 2000, Acta Neuropathologica.
[44] G. Hellermann,et al. Physiological levels of β-amyloid induce cerebral vessel dysfunction and reduce endothelial nitric oxide production , 2001 .
[45] P. Weigel,et al. Microvessels from Alzheimer's disease brains kill neurons in vitro. , 1999, The American journal of pathology.
[46] W. Wendling,et al. Effects of prostaglandin F2 alpha and thromboxane A2 analogue on bovine cerebral arterial tone and calcium fluxes. , 1991, Stroke.
[47] D. Selkoe,et al. Amyloid β-Protein and the Genetics of Alzheimer's Disease* , 1996, The Journal of Biological Chemistry.
[48] T. Town,et al. Soluble β-amyloid peptides mediate vasoactivity via activation of a pro-inflammatory pathway , 2000, Neurobiology of Aging.
[49] T. Town,et al. Aβ Vasoactivity: An Inflammatory Reaction , 2000 .
[50] J. van Ryn,et al. Clinical experience with cyclooxygenase-2 inhibitors , 1999, Inflammation Research.
[51] P. Weigel,et al. Cerebrovasculature‐mediated Neuronal Cell Death , 2000, Annals of the New York Academy of Sciences.
[52] P. Mcgeer,et al. Inflammation of the brain in Alzheimer's disease: implications for therapy , 1999, Journal of leukocyte biology.
[53] R. Kalaria. The role of cerebral ischemia in Alzheimer’s disease , 2000, Neurobiology of Aging.
[54] L. Lue,et al. Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer’s Disease , 1999 .
[55] P. Grammas. A damaged microcirculation contributes to neuronal cell death in Alzheimer’s disease☆ , 2000, Neurobiology of Aging.
[56] Patrick L. McGeer,et al. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease , 1996, Neurology.
[57] C. Masters,et al. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease , 1999, Annals of neurology.
[58] T. Miyakawa,et al. Observations of Microvessels in the Brain with Alzheimer's Disease by the Scanning Electron Microscopy , 1991, The Japanese journal of psychiatry and neurology.
[59] P. Hedera,et al. Differential degeneration of the cerebral microvasculature in Alzheimer's disease. , 1995, Neuroreport.
[60] Luz Claudio,et al. Ultrastructural features of the blood-brain barrier in biopsy tissue from Alzheimer's disease patients , 1995, Acta Neuropathologica.
[61] P. Aisen,et al. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain , 1998, Neuroscience.
[62] P. Grammas,et al. Inflammatory factors are elevated in brain microvessels in Alzheimer’s disease , 2001, Neurobiology of Aging.
[63] D. Paris,et al. Pro-inflammatory effect of freshly solubilized β-amyloid peptides in the brain , 2002 .
[64] J. Overmier,et al. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice , 2001, Neurobiology of Aging.
[65] Douglas Walker,et al. Inflammation and Alzheimer's disease pathogenesis , 1996, Neurobiology of Aging.
[66] P. Aisen,et al. Regional distribution of cyclooxygenase‐2 in the hippocampal formation in Alzheimer's disease , 1999, Journal of neuroscience research.